EP3687540A4 - HETEROARYL COMPOUNDS USED AS CXCR4 INHIBITORS, COMPOSITION AND METHOD OF USE THEREOF - Google Patents

HETEROARYL COMPOUNDS USED AS CXCR4 INHIBITORS, COMPOSITION AND METHOD OF USE THEREOF Download PDF

Info

Publication number
EP3687540A4
EP3687540A4 EP18859565.6A EP18859565A EP3687540A4 EP 3687540 A4 EP3687540 A4 EP 3687540A4 EP 18859565 A EP18859565 A EP 18859565A EP 3687540 A4 EP3687540 A4 EP 3687540A4
Authority
EP
European Patent Office
Prior art keywords
composition
compounds used
heteroaryl compounds
cxcr4 inhibitors
cxcr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18859565.6A
Other languages
German (de)
French (fr)
Other versions
EP3687540A1 (en
Inventor
Xiaohu Zhang
Jiyue ZHENG
Haikuo MA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cgenetech Suzhou China Co Ltd
Original Assignee
Cgenetech Suzhou China Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201810265417.9A external-priority patent/CN110317191B/en
Priority claimed from CN201810710340.1A external-priority patent/CN110669036B/en
Priority claimed from CN201811034891.7A external-priority patent/CN109553604B/en
Application filed by Cgenetech Suzhou China Co Ltd filed Critical Cgenetech Suzhou China Co Ltd
Publication of EP3687540A1 publication Critical patent/EP3687540A1/en
Publication of EP3687540A4 publication Critical patent/EP3687540A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18859565.6A 2017-09-25 2018-09-24 HETEROARYL COMPOUNDS USED AS CXCR4 INHIBITORS, COMPOSITION AND METHOD OF USE THEREOF Pending EP3687540A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710875041 2017-09-25
CN201810265417.9A CN110317191B (en) 2018-03-28 2018-03-28 Pyridine heterocyclic compound and application thereof as CXCR4 inhibitor
CN201810710340.1A CN110669036B (en) 2018-07-02 2018-07-02 A class of heterocyclic compounds with CXCR4 signaling pathway inhibitory activity and their applications
CN201811034891.7A CN109553604B (en) 2017-09-25 2018-09-05 4-aminopyrimidine derivatives as CXCR4 inhibitors and uses thereof
PCT/US2018/052503 WO2019060860A1 (en) 2017-09-25 2018-09-24 Heteroaryl compounds as cxcr4 inhibitors, composition and method using the same

Publications (2)

Publication Number Publication Date
EP3687540A1 EP3687540A1 (en) 2020-08-05
EP3687540A4 true EP3687540A4 (en) 2021-04-21

Family

ID=65809950

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18859565.6A Pending EP3687540A4 (en) 2017-09-25 2018-09-24 HETEROARYL COMPOUNDS USED AS CXCR4 INHIBITORS, COMPOSITION AND METHOD OF USE THEREOF

Country Status (3)

Country Link
EP (1) EP3687540A4 (en)
KR (1) KR102678977B1 (en)
WO (1) WO2019060860A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585387A4 (en) 2017-02-21 2020-08-12 Emory University CHEMOKIN CXCR4 RECEPTOR MODULATORS AND USE THEREOF
US11649235B2 (en) 2018-03-19 2023-05-16 Emory University Pan-tropic entry inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
SMT202500271T1 (en) 2020-07-02 2025-09-12 Incyte Corp Tricyclic urea compounds as jak2 v617f inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (en) 2021-02-25 2023-07-05 Incyte Corp SPIROCYCLIC LACTAMS AS JAK2 INHIBITORS V617F
CN119173514A (en) 2022-03-17 2024-12-20 因赛特公司 Tricyclic urea compounds as JAK2 V617F inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023400A2 (en) * 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
WO2006026703A2 (en) * 2004-09-02 2006-03-09 Smithkline Beecham Corporation Chemical compounds
WO2006076131A2 (en) * 2004-12-17 2006-07-20 Smithkline Beecham Corporation Chemical compounds
WO2007027999A2 (en) * 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds
CN102675305A (en) * 2011-03-08 2012-09-19 中国科学院上海药物研究所 Imidazopyridine compounds, as well as preparation method and application thereof
CN103570683A (en) * 2012-07-30 2014-02-12 中国科学院上海药物研究所 Multi-substituted amine compound, as well as preparation method and use thereof
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051387A1 (en) * 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
AU2009228034A1 (en) * 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
WO2010025416A1 (en) * 2008-08-29 2010-03-04 Genzyme Corporation Cxcr4 antagonists for kidney injury
WO2017011517A1 (en) * 2015-07-16 2017-01-19 Emory University Bis-amines, compositions, and uses related to cxcr4 inhibition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023400A2 (en) * 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
WO2006026703A2 (en) * 2004-09-02 2006-03-09 Smithkline Beecham Corporation Chemical compounds
WO2006076131A2 (en) * 2004-12-17 2006-07-20 Smithkline Beecham Corporation Chemical compounds
WO2007027999A2 (en) * 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds
CN102675305A (en) * 2011-03-08 2012-09-19 中国科学院上海药物研究所 Imidazopyridine compounds, as well as preparation method and application thereof
CN103570683A (en) * 2012-07-30 2014-02-12 中国科学院上海药物研究所 Multi-substituted amine compound, as well as preparation method and use thereof
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019060860A1 *

Also Published As

Publication number Publication date
WO2019060860A1 (en) 2019-03-28
KR102678977B1 (en) 2024-06-28
EP3687540A1 (en) 2020-08-05
KR20200058443A (en) 2020-05-27

Similar Documents

Publication Publication Date Title
EP3687540A4 (en) HETEROARYL COMPOUNDS USED AS CXCR4 INHIBITORS, COMPOSITION AND METHOD OF USE THEREOF
FR24C1009I2 (en) COMPOUNDS USED AS KINASE INHIBITORS
EP3718572A4 (en) NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, METHOD OF PREPARATION AND USE
EP3681499A4 (en) COMPOUNDS USED AS RAS INHIBITORS AND THEIR USE
MA47233A (en) AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS USED AS EHMT2 INHIBITORS AND THEIR METHODS OF USE
JOP20250289A1 (en) New crystal images
MA55633A (en) SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS USED AS ROCK INHIBITORS
MA56032A (en) COMPOUNDS, COMPOSITIONS AND METHODS OF USE
EP3768267A4 (en) KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE
MA55695A (en) CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
ZA202109003B (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
EP3727401A4 (en) CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
EP3402799A4 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RSV
EP3807253A4 (en) CYANO QUINOLINE AMIDE COMPOUNDS USED AS HER2 INHIBITORS AND METHODS OF USE
EP3630962A4 (en) CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
MA48942A (en) THERAPEUTIC COMPOUNDS, ASSOCIATED COMPOSITIONS AND METHODS OF USE
MA41677A (en) ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS
EP3337787A4 (en) HETEROCYCLIC PYRAZOLO COMPOUNDS CONDENSED AS ERK INHIBITORS
EP2968357A4 (en) S-IMINO-S-OXO IMINOTHIAZINE COMPOUNDS AS INHIBITORS OF THE SITE SS CLEAVING ENZYME OF THE APP, COMPOSITIONS, AND USE THEREOF
BR112017026682A2 (en) new bicyclic compounds as dual action inhibitors of atx / ca
EP3964518C0 (en) CD73 INHIBITOR, ITS PREPARATION PROCESS AND ITS USE
EP3487498A4 (en) HETERARYARYLIC COMPOUNDS FOR USE AS NECROSIS INHIBITORS, COMPOSITION AND APPLICATION THEREOF
EP3302488A4 (en) NOVEL USE OF ARYL-QUINOLINE DERIVATIVES AS INHIBITORS OF IMITATION OF VASCULOGENIC FACTORS
EP3710006A4 (en) SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
EP3906028A4 (en) KINASE INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/444 20060101AFI20210208BHEP

Ipc: A61P 11/00 20060101ALI20210208BHEP

Ipc: A61P 35/00 20060101ALI20210208BHEP

Ipc: C07D 401/14 20060101ALI20210208BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210324

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/444 20060101AFI20210318BHEP

Ipc: C07D 401/14 20060101ALI20210318BHEP

Ipc: A61P 11/00 20060101ALI20210318BHEP

Ipc: A61P 35/00 20060101ALI20210318BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220802